Role of bronchoscopy during non invasive ventilation in hypercapnic respiratory failure  by Rady, W. et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2014) 63, 1003–1011HO ST E D  BY
The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLERole of bronchoscopy during non invasive
ventilation in hypercapnic respiratory failure* Corresponding author.
Peer review under responsibility of The Egyptian Society of Chest
Diseases and Tuberculosis.
http://dx.doi.org/10.1016/j.ejcdt.2014.06.015
0422-7638 ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.W. Rady a, A. Abouelela a, A. Abdallah b,*, W. Youssef aa Alexandria University, Critical Care Medicine Department, Alexandria, Egypt
b Alexandria University, Pulmonary Medicine Department, Alexandria, EgyptReceived 4 March 2014; accepted 24 June 2014
Available online 22 July 2014KEYWORDS
Bronchoscopy;
Ventilation;
Respiratory failureAbstract Introduction: Non invasive positive pressure ventilation (NIPPV) is the ﬁrst line treat-
ment for hypercapnic acute respiratory failure (ARF) secondary to COPD exacerbation in selected
patients. Limited data exist supporting the use of ﬁberoptic bronchoscopy (FOB) during this clinical
setting. The aim of this study is to assess the role of FOB during NIPPV in patients with decom-
pensated COPD acute exacerbation.
Methods: This study is a randomized prospective case control pilot study carried out on 50
patients - admitted to critical care units at Alexandria University Hospital, Egypt - suffering from
hypercapnic ARF secondary to COPD exacerbation with Kelly Matthay Score from 2 to 4. All
patients received NIPPV. Patients were divided randomly into 2 equal groups: group I (cases)
(25 patients) was subjected to additional intervention of early FOB during the ﬁrst 6–12 h from
admission while group II (control) (25 patients) received the conventional treatment and NIPPV
only. Outcome parameters measured were changes in ABG data, duration of NIPPV, rate of its suc-
cess, ICU stay and mortality as well as the safety of FOB and possible complications.
Results: No signiﬁcant difference was detected between the 2 groups regarding the baseline char-
acteristics. No serious complications happened from FOB, and Oxygen desaturation happened in 4/
25 patients (16%), Tachycardia in 2/25 patients (8%). In group I, 23 patients (92%) were success-
fully weaned from NIPPV versus 16 patients (64%) in group II (p= 0.037). Total duration of NIP-
PV was 28.52 h in group I versus 56.25 h in group II (p= 0.001). Length of ICU stay was 4.84 days
in group I versus 8.68 days in group II (p= 0.001). Only 1 patient died in group I versus 3 patients
in group II (p= 0.609).
Conclusion: The early application of FOB during NIPPV in patients with ARF due to COPD
exacerbation was shown to be safe. Signiﬁcant improvement in the outcome of patients who under-
went FOB was noticed in terms of improved ABG data, shorter duration of NIPPV, higher percent-
age of success and shorter ICU stay while no signiﬁcant difference was detected in mortality.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
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The American Thoracic Society, European Respiratory Soci-
ety, and the British Thoracic Society have each deﬁned COPD
using slightly different wordings and approaches over the past
15 years.The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) a report produced by the National Heart,
Lung, and Blood Institute (NHLBI) and the World Health
Organization (WHO) deﬁnes COPD as a preventable and
treatable disease with some signiﬁcant extrapulmonary effects
that may contribute to the severity in individual patients. Its
pulmonary component is characterized by airﬂow limitation
that is not fully reversible. The airﬂow limitation is usually
progressive and associated with an abnormal inﬂammatory
response of the lungs to noxious particles or gases [1].
The Global Initiative for Chronic Obstructive Lung Disease
(GOLD) – a report produced by the National Heart, Lung,
and Blood Institute (NHLBI) and the World Health Organiza-
tion (WHO) – deﬁnes an exacerbation of chronic obstructive
pulmonary disease (COPD) as an acute increase in symptoms
beyond normal day-to-day variation .This generally includes
an acute increase in one or more of the following cardinal
symptoms: cough increases in frequency and severity, sputum
production increases in volume and/or changes character, and
dyspnea increases [2].
It is estimated that 50–60 percent of exacerbations are due
to respiratory infections (mostly bacterial like Haemophilus
inﬂuenzae, Moraxella catarrhalis, Streptococcus pneumoniae,
Pseudomonas aeruginosa and Enterobacteriaceae and viral like
rhinoviruses. Inﬂuenza, parainﬂuenza, coronavirus, and ade-
novirus), 10 percent are due to environmental pollution, and
30 percent are of unknown etiology [3].
Some COPD exacerbations of unknown etiology may be
related to other medical conditions, such as myocardial ischemia,
heart failure, aspiration, or pulmonary embolism [4]. Patients
with COPD who present to the hospital with acute worsening
of dyspnea should be evaluated for potential alternative diagno-
ses, such as heart failure, pulmonary thromboembolism, and
pneumonia. This was illustrated in an autopsy study of 43
patients with COPD who died within 24 h of admission for a
COPD exacerbation .The primary causes of death were heart
failure, pneumonia, pulmonary thromboembolism, and COPD
in 37, 28, 21, and 14 percent, respectively [2].
Noninvasive positive pressure ventilation (NIPPV) refers to
mechanical ventilation delivered through a noninvasive inter-
face, such as a face mask, nasal mask, or nasal prongs; it is
more comfortable allowing expectoration, eating, speech and
prevents rebreathing than full face mask. The face mask is gen-
erally preferred over a nasal mask or nasal prongs during the
initiation of NIV for several reasons. Most patients with acute
respiratory failure are mouth breathers; therefore, NIV deliv-
ered by a nasal mask results in a large air leak through the
mouth and a worse outcome. The nasal air passages offer sig-
niﬁcant resistance to airﬂow, which can mitigate the beneﬁcial
effects of NIPPV if a low level of positive airway pressure is
used. There are two principal forms used: Pressure support
ventilation (PSV) and bilevel positive airway pressure (BiPAP).
PSV is the most common mode chosen by clinicians who want
to maximize patient comfort and synchrony. Both provide
positive airway pressure during the respiratory cycle, but
BiPAP offers pressure in a biphasic manner, with higherpressures during inspiration than expiration. Studies in
patients with obstructive lung disease indicate that low-level
CPAP offsets the detrimental effects of auto-positive end-expi-
ratory pressure, which are caused by gas trapped in alveoli at
end expiration and decreases inspiratory work of breathing.
The addition of inspiratory pressure support to CPAP (or
BiPAP) generally improves tidal volume in proportion to the
amount of pressure applied .Both CPAP and BiPAP have been
used as an alternative to intubation in patients with a variety
of respiratory conditions, including congestive heart failure
with pulmonary edema and COPD, avoiding the complica-
tions associated with endotracheal intubation. It improves
numerous clinical outcomes and is the preferred method of
ventilatory support in many patients with an acute exacerba-
tion of COPD complicated by hypercapnic acidosis [5,6].
NIPPV has physiologic beneﬁts. Respiratory mechanics
measured after the initiation of NIPPV demonstrate a
decreased respiratory rate, an increased tidal volume, and
increased minute ventilation. In addition, the arterial oxygen
tension (PaO2) tends to increase as the PaCO2 decreases.
The pressure support level should be increased until patient’s
respiratory rate is below 30 breaths per min because this respi-
ratory rate indicates that the inspiratory effort has been
reduced to a reasonable level. However, the expiratory effort
of patients with COPD may increase when the pressure sup-
port is increased, which makes selection of the optimal pres-
sure support level difﬁcult [7].
Flexible ﬁberoptic bronchoscopy (FOB) has become an
indispensable tool in the optimal management of intensive care
unit (ICU) patients with both diagnostic and therapeutic goals.
Its safety and usefulness, in well-trained hands with appropri-
ate precautions, have led to its increasing use even in unstable
and mechanically ventilated patients. Currently, rigid bron-
choscopes are not often used except for the management of
massive hemoptysis, removal of tracheobronchial foreign
bodies, laser photoresection for obstructing endobronchial
tumours, dilatation of tracheobronchial strictures and place-
ment of airway stents [8,9].
In bronchoalveolar lavage (BAL), the FOB is wedged into a
subsegmental bronchus and multiple aliquots (20–50 ml) of sal-
ine are instilled into that lung segment and then withdrawn by
suction. The centrifuged BAL ﬂuid is stained for opportunistic
pathogens and cultured. Although 200 ml was once considered
the maximum, recent literature demonstrates that lavage vol-
umes of up to 300 ml are well tolerated. Patients should not
eat or drink anything 6–12 h before procedure. Also you to try
avoid any aspirin, ibuprofen, or other blood-thinning drugs
before procedure. After procedure, your gag reﬂex will return.
However, until it does, patients should not eat or drink anything.
To test if the gag reﬂex has returned, place a spoon on the back
of your tongue for a few seconds with light pressure. If patient
does not gag, wait 15 min and try it again [10].
So, the aim of this work is to assess the role of early ﬁberoptic
bronchoscopy during non invasive ventilation in acute exacerba-
tion of COPD patients in terms of effectiveness and safety.
Patients
This prospective case control study was carried out on 50
patients, suffering from hypercapneic acute respiratory failure
as a result of acute exacerbation of chronic obstructive pul-
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ventilation admitted consecutively to critical care units at
Alexandria university main hospital.
Patients were divided into two groups:
 Group I (cases): 20 patients received conventional medical
treatment plus early ﬁberoptic bronchoscopy during non
invasive ventilation.
 Group II (controls): 20 patients received only conventional
medical treatment and noninvasive ventilation.
The inclusion criteria
All COPD patients met all the following criteria while breath-
ing oxygen via a venturi mask.
a) pH less than 7.33 and (PaCO2) above 55 mmHg.
b) (PaO2)/(FiO2) ratio less than 200.
c) Dyspnea at rest with respiratory rate (RR) above 25
breaths/min.
d) Use of accessory respiratory muscles.
e) Mild hypercapneic encephalopathy Kelly Matthay score
[11] between 2 & 4.
f) Inability to spontaneously clear airways from excessive
secretions, as expressed by the lowest score of an arbi-
trary cough efﬁciency scale evaluated by the nurses on
the basis of the volume of the expelled sputum after
three hard coughing efforts (1 = less than 2 ml;
2 = between 2 and 6 ml and; 3 = more than6 ml).
Methods
Patients were divided into two groups:
 Group I (cases): 25 patients received medical treatment and
early ﬁberoptic bronchoscopy within 12 h of starting non
invasive ventilation.
 Group II (control): 25 patients received only medical treat-
ment and non invasive ventilation.
Medical therapy
All patients received medical therapy consisting of:
1) Controlled oxygen therapy.
2) Nebulized bronchodilator (salbutamol and anticholiner-
gic drugs).
3) Intravenous corticosteroids.
4) Antibiotic strategy was based on empirical intravenous
administration of levoﬂoxacin plus b-lactam (for penicil-
lin-allergic patients: levoﬂoxacin plus aztreonam or carba-
penem), unless some risk factors for Pseudomonas
aeruginosa were identiﬁed (ciproﬂoxacin plus anti-pseudo-
monal b-lactam). Antibiotic-therapy was later adjusted
according to the results of bacterial cultures [12].
5) Subcutaneous low-molecular weight heparin; and ther-
apy for comorbidities if necessary.
6) Anti stress ulcer.Before ﬁberoptic bronchoscopy (FOB)
Non invasive ventilation was delivered in a pressure support
(PS) mode with positive end-expiratory pressure (PEEP) or
pressure controlled mode (BiPAP) via a well-ﬁtting full-face
mask with the addition of a heated humidiﬁer [13]. PS or inspi-
ratory positive airway pressure (IPAP) was initially set at
10 cm H2O and then titrated up to achieve an expiratory tidal
volume of 8–10 ml/kg and a respiratory rate below 25 breaths/
min to a maximum of 25 cm H2O depending on clinical and
arterial blood gases (ABGs) response and patient tolerance.
PEEP or expiratory positive airway pressure (EPAP) was
always set at 5 up to 10 cm H2O to achieve optimal ventilation
and oxygenation. Back-up RR is set at a 14–18 breaths/min.
FiO2 was initially set at 0.50–0.60 then titrated down till reach-
ing 0.30 or arterial oxygen saturation ranging between 90%
and 92%. The time from initiation of NIV to the bronchos-
copy procedure was recorded. Following bronchoscopy all
patients remained on noninvasive ventilatory support for at
least two hours.
During FOB bronchoscopy procedure
Before, during and after bronchoscopy, level of conscious, the
electrocardiogram, arterial blood pressure, pulse oximeter and
ventilatory parameters (FiO2, ventilator mode, inspiratory and
expiratory pressures, tidal volume, and respiratory rate) were
continuously monitored. Arterial samples were drawn for
blood gas analysis from the arterial line at baseline, before
and 2 h after procedure. Ventilator settings were adjusted to
optimize ventilatory support. The fraction of inspired oxygen
(FiO2) was increased to 100% just before and throughout
the procedure. FOB was performed after the patients had
adapted to NIPPV. A swivel connector (T-adapter) was
inserted between the ventilator tubing and the mask to allow
the insertion of the bronchoscope. Sedation was achieved in
all cases using midazolam ranging from 2.5 mg up to 10 mg
in incremental doses to achieve conscious sedation, before
and after the insertion of the bronchoscope and can be
repeated every three to ﬁve minutes according to patient toler-
ance. Topical anesthesia of the nasopharynx (10% lidocaine
spray solution) and larynx (5 ml of 2% lidocaine hydrochlo-
ride were instilled via the bronchoscope channel to the laryn-
geal, tracheal and bronchial mucosa, not exceeding an
overall dose of 200 mg) was performed before advancing the
bronchoscope into the tracheobronchial tree. Firstly, a careful
suction of bronchial secretions was performed to fully clear
airways. Then, the tip of the FOB was wedged into the bron-
chial sub segment. Bronchoalveolar lavage (BAL) was per-
formed by sequential instillation of ﬁve aliquots of 20 mL
saline solution at room temperature. The retrieved ﬂuid was
sent immediately to the microbiology laboratory for micro-
scopic analysis and culturing. The isolated bacteria with a
count of 104 CFU/mL or more of the BAL ﬂuid were consid-
ered as etiological agents of infection. The duration of bron-
choscopy was deﬁned as the time from insertion until
removal of the bronchoscope from the tracheobronchial tree
[14,15].
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After the bronchoscopic procedures, the FiO2 decreased in
order to maintain arterial oxygen saturation measured by the
pulse oximetry (SpO2) at 90–92%. Routine chest physiother-
apy was done to facilitate expectoration. Electrocardiogram,
SpO2, and noninvasive blood pressure were monitored contin-
uously. ABGs were sampled as follows: at baseline, before, and
at the end of FBO; and subsequently as clinically indicated.
Weaning
NIPPV was applied continuously at least during the ﬁrst 12–
24 h. Once clinical status and ABGs had improved, NIPPV
was administered intermittently with sessions lasting two to
six hours three times daily. Then PS or IPAP was reduced pro-
gressively. NIPPV weaning was considered successful within
three days of ventilation or more when all the following crite-
ria are met for longer than 24 h while breathing with oxygen
(FiO2 0.28): pH above 7.35, SpO2 above 90%, RR less than
20 breaths/min, fully conscious, efﬁcient cough with a signiﬁ-
cant amount of sputum, radiographic improvement of chest
infection and stable hemodynamic status [15].
Failure of NIPPV trial was considered if at least one of the
following criteria for intubation was met: cardiac arrest or
severe hemodynamic instability; respiratory arrest or gasping;
and/or worsening of ABGs or worsening of sensorium level
during NIPPV.
Comparison between the two groups of the study regarding
the ABG data, the success of NIPPV in avoiding invasive
mechanical ventilation, the duration of NIPPV, length of
ICU stay and mortality were recorded and analyzed statisti-
cally using appropriate statistical tests.
Results
This comparative case control prospective study was con-
ducted on 50 patients admitted to the Critical Care Medicine
Department &Respiratory Intensive Care Unit in Alexandria
Main University Hospital by acute exacerbation of chronic
obstructive pulmonary disease (COPD) and fulﬁlling the crite-
ria for application of non invasive positive pressure ventilation
(NIPPV).
Patients were randomly assigned into two equal groups by
allocated randomization:
 Group I (cases): 25 patients received conventional medical
treatment plus early ﬁberoptic bronchoscopy during non
invasive ventilation.
 Group II (controls): 25 patients received only conventional
medical treatment and noninvasive ventilation.
Comparison between the two studied groups according to arterial
blood gases at different periods
At admission, patients were initially managed with repeated
sittings of bronchodilator nebulizer through a face mask with
O2 ﬂow 5–10 L/min, pH in group I ranged between 7.23 and
7.32 with a mean value of 7.27 ± 0.03 while in group II, pHranged between 7.22 and 7.32 with a mean value of
7.28 ± 0.03 with no statistical difference between both groups
(p 0.059). Six to twelve hours from admission during NIV
(before Bronchoscopy), pH in group I ranged between 7.25
and 7.34 with a mean value of 7.30 ± 0.03 while in group II,
pH ranged from 7.10 to 7.36 with a mean value of
7.29 ± 0.08 with no signiﬁcant statistical difference between
both groups (p 0.561). 8–14 h from admission during NIV
(2 h after bronchoscopy in group I), Improvement of pH in
group I ranged between 7.33 and 7.46 with a mean value of
7.38 ± 0.04 which was signiﬁcantly better than values in group
II, as pH ranged from 7.31 to 7.38 with a mean value of
7.36 ± 0.02 (p 0.015).
At admission on face mask with O2 ﬂow 5–10 L/min, PCO2
in group I ranged between 64.0 and 92.0 mmHg with a mean
value of 77.24 ± 08.42 mmHg while in group II, PCO2 ranged
between 60.0 and 92.0 mmHg with a mean value of
72.76 ± 09.04 mmHg with no statistical difference between
both groups (p 0.076). Six to twelve hours from admission dur-
ing NIV (before bronchoscopy), PCO2 in group I ranged
between 52.0 and 76.0 mmHg with a mean value of
70.12 ± 7.41 mmHg while in group II, PCO2 ranged from
52.0 to 112.0 mmHg with a mean value of 71.72 ±
16.43 mmHg with no signiﬁcant statistical difference between
both groups (p 0.659). 8–14 h from admission during NIV
(2 h after bronchoscopy in group I), PCO2 in group I ranged
between 40.0 and 67.0 mmHg with a mean value of
55.68 ± 7.76 mmHg while in group II, PCO2 ranged from
56.0 to 71.0 mmHg with a mean value of 63.63 ± 5.11 mmHg
with signiﬁcant statistical lower values of PCO2 in group I
(p 0.001).
At admission on face mask with O2 ﬂow 5–10 L/min, O2
index in group I ranged between 135.0 and 162.0 with a
mean value of 149.64 ± 07.97 while in group II, O2 index
ranged between 122.0 and 170.0 with a mean value of
147.64 ± 10.60 with no statistical difference between both
groups (p 0.455). Six to twelve hours from admission during
NIV (before bronchoscopy), O2 index in group I ranged
between 140.0 and 205.5 with a mean value of 169.16 ±
19.51 while in group II, O2 index ranged from 72.0 to 227.0
with a mean value of 159.52 ± 53.98 with no signiﬁcant statis-
tical values between both groups (p 0.408). 8–14 h from admis-
sion during NIV (2 h after bronchoscopy in group I), O2 index
in group I ranged between 180.0 and 300.0 with a mean value
of 242.24 ± 039.27 while in group II, O2 index ranged from
190.0 to 245.0 with a mean value of 221.94 ± 17.61 with a sig-
niﬁcant statistical higher value in group I (p 0.030).
Incidence of complications during FOB
Few complications developed during FOB procedure. Desatu-
ration of arterial blood (SaO2 less than 88%) displayed on the
monitor occurred in 4/25 patients (16%). Increased heart rate
more than 120 beats/minute occurred only in 2/25 cases (8%).
Ventilator settings before and after FOB among group I
Inspiratory positive airway pressure (IPAP) before FOB ran-
ged between 15.0 and 22.0 cm H2O with a mean value of
19.56 ± 2.08 while after FOB, it ranged between 10.0 and
20.0 with a mean value of 14.60 ± 3.48 with a signiﬁcant sta-
tistical difference (p< 0.001). Expiratory positive airway pres-
sure (EPAP) before FOB was ranging from 7.0 to 10.0 cm H2O
Table 1 Neurologic status score.
Grade
No.
Description
1 Alert, follows complex three-step command (i.e., take a sheet of paper, tear it into
four pieces and place three pieces in one pile)
2 Alert, follows simple commands (show me two ﬁngers)
3 Lethargic, but arousable and follows simple commands
4 Stuporous, i.e., only intermittently follow simple command even with vigorous
attempts to arouse patient
5 Comatose, brain stem intact
6 Comatose with brain stem dysfunction
Table 2 Comparison between the two studied groups according to APACHE II score and Kelly Matthay score.
Group I (n= 25) Group II (n= 25) p
No. % No. %
APACHE II score
Min.–Max. 7.0–21.0 11.0–20.0 0.432
Mean ± SD 15.24 ± 3.03 15.88 ± 2.67
Median 16.0 15.0
Kelly Matthay score
2 7 28.0 8 32.0 –
3 16 64.0 13 52.0
4 2 8.0 4 16.0
Min.–Max. 2.0–4.0 2.0–4.0 0.825
Mean ± SD 2.80 ± 0.58 2.84 ± 0.69
Median 3.0 3.0
p: p value for Student t-test.
Table 3 Comparison between the two studied groups accord-
ing to PH at different periods of follow up.
Group I (n= 25) Group II (n= 25) p
At admission (pre NIPPV)
Min.–Max. 7.23–7.32 7.22–7.32 0.059
Mean ± SD 7.27 ± 0.03 7.28 ± 0.03
Median 7.26 7.28
6–12 h later During NIPPV (pre FOB)
Min.–Max. 7.25–7.34 7.10–7.36 0.561
Mean ± SD 7.30 ± 0.03 7.29 ± 0.08
Median 7.30 7.30
8–14 h from admission (Post FOB in group I)
Min.–Max. 7.33–7.46 7.31–7.38 <0.001*
Mean ± SD 7.38 ± 0.04 7.33 ± 0.02
Median 7.37 7.36
p: p value for Student t-test *: Statistically signiﬁcant at p 6 0.05.
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niﬁcantly less as it ranged between 5.0 and 7.0 with a mean
value of 5.80 ± 1.0 (p< 0.001). Frequency before FOB was
ranging between 20 and 25 breaths per minute with a mean
value of 24.68 ± 1.14 which was signiﬁcantly less after FOB,
as it ranged between 12 and 22 with a mean value of
16.52 ± 2.25 (p< 0.001). Also fraction of inspired oxygen
(FiO2) showed a signiﬁcant decrease after the bronchoscopy
as it was ranging from 40% to 50% with a mean value of
42.40 ± 4.36 before FOB versus 35–40% with a mean value
of 37.20 ± 2.53 after FOB (p< 0.001).
Outcome
Outcome was evaluated as regards success of weaning from
NIV, total duration of NIV in succeeded cases, length of
ICU stay, and mortality rate during hospitalization.
In group I, 23 cases (92%) have been successfully weaned
from NIPPV while only 2 cases(8%) failed on NIPPV and
intubated while in group II ,16 cases (64%) have been suc-
cessfully weaned from NIPPV while 9 cases (36%) failed on
NIPPV and intubated with a signiﬁcant statistical difference
in favor of group I (p= 0.037). Total duration of NIV in
succeeded cases in group I ranged between15.0 and 48.0 h
with a mean value of 28.52 ± 10.63 while in group II, it ran-
ged from 24.0 to 96.0 h with a mean value of 56.25 ± 21.34
with a signiﬁcant statistical value between both groups (p
0.001). As regards the length of Intensive care unit (ICU) stayin group I, it ranged between 2.0 and 25.0 days with a mean
value of 4.84 ± 4.51 while in group II it ranged from 4.0 to
35.0 days with a mean value of 8.68 ± 7.18 with a signiﬁcant
statistical value between both groups (p 0.001). Only one
case (4%) in group I died versus 3 cases (12%) in group II
with no signiﬁcant statistical value between both groups
(p= 0.609).
Table 4 Comparison between the two studied groups accord-
ing to PCO2 at different periods of follow up.
Group I (n= 25) Group II (n= 25) p
At admission (pre NIPPV)
Min.–Max. 64.0–92.0 60.0–92.0 0.552
Mean ± SD 74.24 ± 8.42 72.76 ± 9.04
Median 76.0 71.0
6–12 h later During NIPPV (pre FOB)
Min.–Max. 52.0–76.0 52.0–112.0 0.659
Mean ± SD 70.12 ± 7.41 71.72 ± 16.43
Median 69.0 69.0
8–14 h from admission (Post FOB in group I)
Min.–Max. 40.0–67.0 56.0–71.0 0.001*
Mean ± SD 55.68 ± 7.76 63.63 ± 5.11
Median 56.0 63.50
Table 5 Comparison between the two studied groups accord-
ing to O2 index at different periods of follow up.
Group I (n= 25) Group II (n= 25) p
At admission (pre NIPPV)
Min.–Max. 135.0–162.0 122.0–170.0 0.455
Mean ± SD 149.64 ± 7.97 147.64 ± 10.60
Median 150.0 147.0
6–12 h later During NIPPV(pre FOB)
Min.–Max. 140.0–205.0 72.0–227.0 0.408
Mean ± SD 169.16 ± 19.51 159.52 ± 53.98
Median 167.0 175.0
8–14 h from admission (Post FOB in group I)
Min.–Max. 180.0–300.0 190.0–245.0 0.030*
Mean ± SD 242.24 ± 39.27 221.94 ± 17.61
Median 243.0 221.0
p: p value for Student t-test *: Statistically signiﬁcant at p 6 0.05.
Table 6 Incidence of complications during FOB.
No. %
Desaturation (SaO2 < 88%) 4 16.0
Sinus tachycardia >120 b/m 2 8.0
Gag and vomiting 0 0.0
Bronchospasm 0 0.0
Pneumothorax 0 0.0
Trauma 0 0.0
Fever 0 0.0
Table 7 Comparison between ventilator settings before and
after FOB among group I.
Before FOB 2 h after FOB p
IPAP(PS above PEEP)
Min.–Max. 15.0–22.0 10.0–20.0 <0.001*
Mean ± SD 19.56 ± 2.08 14.60 ± 3.48
Median 20.0 14.0
EPAP
Min.–Max. 7.0–10.0 5.0–7.0 <0.001*
Mean ± SD 7.60 ± 1.15 5.80 ± 1.0
Median 7.0 5.0
RR
Min.–Max. 20.0–25.0 12.0–22.0 <0.001*
Mean ± SD 24.68 ± 1.14 16.52 ± 2.28
Median 25.0 16.0
FiO2
Min.–Max. 40.0–50.0 35.0–40.0 <0.001*
Mean ± SD 42.40 ± 4.36 37.20 ± 2.53
Median 40.0 35.0
p: p value for Paired t-test *: Statistically signiﬁcant at p 6 0.05.
Table 8 Comparison between the two studied groups according to outcome.
Group I (n= 25) Group II (n= 25) Test of sig.
No. % No. %
Weaning
Failed 2 8.0 9 36.0 FE p= 0.037*
Succeeded 23 92.0 16 64.0
Total duration of NIV in succeeded cases (hours)
Min.–Max. 15.0–48.0 24.0–96.0 p< 0.001*
Mean ± SD 28.52 ± 10.63 56.25 ± 21.34
Median 26.0 48.0
ICU stay (days)
Min.–Max. 2.0–25.0 4.0–35.0 p< 0.001*
Mean ± SD 4.84 ± 4.51 8.68 ± 7.18
Median 4.0 6.0
Mortality during ICU stay
Survived 24 96.0 22 88.0 FE p= 0.609
Died 1 4.0 3 12.0
FE p: p value for Fisher Exact test.
p: p value for Mann Whitney test.
*: Statistically signiﬁcant at p 6 0.05.
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Table 9 Distribution of the studied cases according to BAL
bacteriology among group I.
No. %
BAL bacteriology
No growth 14 56.0
Organism 11 44.0
Staph aureus 3 12
Pseudomonas 3 12
Candida 2 8
E. coli 1 4
Proteus 1 4
Klebsiella 1 4
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Bacteriological study of the BAL revealed no growth in 14/25
cases (56%) while 11/2 cases (44%) had positive ﬁndings.
Staphylococcus auerus in 3 cases, Pseudomonas aeuroginosa
was found in 3 cases while candida was found in 2 cases.
Escherichia coli, Proteus, and Klebsiella were found only once
in 3 different patients.
Discussion
Arterial blood gases’ analysis showed an almost similar base-
line pH with a mean value of 7.27 ± 0.03 in group I versus
7.28 ± 0.03 (p 0.059) in group II. Relative improvement in
the pH was noticed in a similar pattern in both groups after
the application of NIPPV (before bronchoscopy) as mean
value of pH in group I improved to 7.30 ± 0.03 while in group
II, the mean value became 7.29 ± 0.08 with no signiﬁcant
statistical difference between both groups (p= 0.153).
Signiﬁcant difference in pH was noticed in favor of group I
after the bronchoscopy as the mean value of pH was
7.38 ± 0.04 which was signiﬁcantly better than values in group
II, as pH mean value was 7.33 ± 0.02 (p= 0.015). These
changes in pH after the application of the bronchoscopy are
comparable to the study done by Scala et al. [16] as pH was
initially 7.27 improved to 7.29 after application to NIPPV,
it remained 7.29 during bronchoscopy and improved
signiﬁcantly to 7.37 after bronchoscopy (p< 0.05). Scala
et al.’s study was the ﬁrst study performed to assess the role
of FOB during NIPPV in patients with decompensated COPD
while the main difference that the control group in that
study was patients on invasive mechanical ventilation and
community acquired pneumonia was the etiology of decom-
pensation in both studied groups.
Similar changes were noticed in the PCO2 as the initial
mean value in mmHg was 74.24 ± 8.42 improved to
70.12 ± 7.41 after application of NIPPV, with signiﬁcant fur-
ther improvement after the bronchoscopy to 55.68 ± 7.76 in
group I while in group II the readings were 72.76 ± 9.04,
71.72 ± 16.43 and 63.63 ± 5.11, respectively. Signiﬁcant dif-
ference was detected only in the third readings (after doing
the bronchoscopy in group I and nearly at the same time in
group II) with p= 0.001*. Comparing these results with Scala
et al.’s [16] results, we can observe a similarity in the two stud-
ies in the trend of PCO2 in mmHg as it was 76, 75 and 60 in the
initial setting, during NIPPV and after ﬁberoptic bronchos-
copy, respectively.The Oxygenation index was low in both groups at the base-
line with mean values of 149.64 ± 07.97 and 147.64 ± 10.60 in
group I and II, respectively, and then it started to show some
improvement in both groups after the application of the NIP-
PV. Signiﬁcant improvement in oxygenation was seen in group
I compared to group II after doing bronchoscopy in group I as
the mean value was 242.24 ± 39.27 in group I versus
221.94 ± 17.61 in group II (p 0.030). The baseline readings
are comparable to Scala et al.’s [16] study as it was 163 then
increased to 211 during NIPPV, but in contrast to the present
study PaO2/FiO2 dropped after bronchoscopy to 200. This
can be explained by the different timing of sampling post bron-
choscopy in the two studies as we preferred to postpone the
sampling in the current study 2 h post bronchoscopy as long
as no signiﬁcant drop in oxygen saturation was recorded by
oximetry to avoid recording the immediate relative desatura-
tion which is expected after bronchoscopy which may mask
the real improvement in oxygenation after clearing the secre-
tions from the lung during bronchoalveolar lavage. Besides
the etiology of decompensation in scala study was community
acquired pneumonia while in my study was different factors
including upper and lower respiratory tract infections, envi-
ronmental factors, atopy, discontinuation of maintenance
medical treatment, and another medical illness.
Considering the limited data on the application of FOB
during NIPPV in COPD patients, it was very important to
record the complications related to FOB in group I of the
study to validate the safety of the procedure in this speciﬁc set-
ting and compare it to overall rates of FBO related complica-
tions in other studies. Few complications developed during
FOB procedure. Desaturation of arterial blood (SaO2 less
than 88%) displayed on the monitor occurred in 4/25 patients
(16%) but it was not clinically signiﬁcant to prevent the com-
pletion of the procedure and it was temporary for few minutes
and easily manageable through temporary increase in PS or
IPAP on NIPPV and enhancing the procedure. Another com-
plication was encountered in the form of increased heart rate
more than 120 beats /minute which occur in only 2/25 cases
(8%) and it was mostly related to the light sedation as it disap-
peared with the administration of extra doses of sedative
drugs. However, no signiﬁcant side effects as vomiting, cardio-
vascular events, pneumothorax and bronchospasm happened
during the procedure. The lack of major complications is con-
sistent with previous reports, which clearly demonstrated the
feasibility and safety of FBO plus BAL performed under the
assistance of NIPPV in patients with severe hypoxemic and
hypercapnic ARF who should have to be otherwise intubated
to allow such invasive procedures [17–21]. This was also in
agreement with a feasibility study done by Hans Jo¨rg Bau-
mann et al. [22] to assess the safety of FOB in patients with
acute hypoxemic respiratory failure requiring NIPPV, the
average duration of bronchoscopy was 7.8 ± 5.5 min (range
3.5–37.0 min). In all cases bronchoscopy was completed with-
out subsequent complications. Two patients developed tran-
sient SaO2 values below 90% during the procedure, the
minimum SaO2 was 84% (Tables 1–6).
The application of FOB in group I patients provided an
additional beneﬁt apart from the drainage of copious secre-
tions and clearing the airway which is the provision of early
accurate sampling of tracheal and alveolar secretions for
microbiological examination. This analysis was greatly helpful
to reach an accurate diagnosis and started a targeted antibiotic
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group II, there was a real problem to get a good sputum sam-
ple from the lower airway not contaminated from the oral
ﬂora. Bacteriological study of the BAL obtained in group I
of the study revealed no growth in 14/25 cases (56%) while
11/25 cases (44%) had positive ﬁndings. Staphylococcus auerus
in 3 cases, Pseudomonas aeuroginosa was found in 3 cases while
candida was found in 2 cases. E. coli, Proteus, Klebsiella were
found only once in 3 different patients. Comparing our micro-
biological data with Scala et al. [16] study where the BAL
results on 15 patients revealed Streptococcus pneumonia in 5
patients (33.3%), Pseudomonas aeuroginosa was found in 4
patients (26.7%) and Staphylococcus auerus in 2 cases
(13.3%), we can notice that the same organisms were isolated
from both studies with the only exception of the Streptococcus
pneumonia which was not isolated from the current study
although it is known to be the ﬁrst causative organism for
community acquired pneumonia and the second common
organism in acute exacerbation after Haemophilus inﬂuenza
bacteria. This ﬁnding might be explained as a high proportion
of patients in the present study were initially admitted to the
hospital in the medical wards and shifted to critical care areas
after developing decompensated respiratory failure and they
might have got gram negative hospital acquired infections dur-
ing their stay in addition to the preceding intake of oral anti-
biotic before admission which may alter classical pattern of
microorganisms.
Analysis of the NIPPV settings before and after the appli-
cation of FOB showed signiﬁcant improvement in all parame-
ters after the procedure in the form of decrease in EPAP,
IPAP, respiratory rate and FiO2 (Table 7) with p value
<0.001 for all parameters. These ﬁndings demonstrate the
clear beneﬁt of the FOB as a synergetic tool with NIPPV to
minimize the work of breathing and oxygen requirement which
was subsequently reﬂected in the form of lower ventilator set-
ting. This beneﬁcial effect was mainly due to clearance of secre-
tions and also due to recruiting the partially atelectatic alveoli
by washing of mucous plugs.
In group II, 16 cases (64%) have been successfully weaned
from NIPPV while 9 cases (36%) failed and required intuba-
tion and mechanical ventilation. Most of them failed due
to accumulation of secretions with subsequent deterioration
of the ABG ﬁndings and depressed consciousness level.
Comparing this failure rate (36%) with another study also
done by Raffaele Scala et al. [23] in 2005 on 80 patients with
acute respiratory failure, NIPPV failed in 23 of 80 patients
(28.8%) which is near to our study. In another study done
by Carlucci A et al. [24] studying Noninvasive versus Conven-
tional Mechanical Ventilation, 43 patients out of 108 patients
(40% of all NIV patients) eventually required endotracheal
intubation while in group I of the present study, the failure rate
on NIPPV is signiﬁcantly less than group II as only 2 patients
failed out of 25 patients (8%). In Scala et al.’s [16] study which
is the only study done to assess the effect of early FBO during
NIPPV, the technique failed in 3 of 15 patients (20%). The dis-
crepancy between the ratios in the two studies cannot be
explained due to the small number of patients which make
any statistical analysis or correlation unreliable. Besides the
etiology of decompensation in scala study was community
acquired pneumonia while in my study was different factors
which were less medically serious than pneumonia. The total
duration of NIV in succeeded cases in group I (23 patients)ranged between 15.0 and 48.0 h with a mean value of
28.52 ± 10.63 while in group II (16 patients), it ranged from
24.0 to 96.0 h with a mean value of 56.25 ± 21.34 with a sig-
niﬁcant statistical value between both groups (p 0.001) denot-
ing the possible beneﬁcial effect of FOB in facilitation of faster
weaning after removing the secretions and improvement of
blood gases. The duration of NIPPV in group II is more or less
comparable to Raffaele Scala et al.’s [23] study as NPPV was
delivered for a median duration of 40.75 h (21.63 to 73 h)
(mean duration for the ﬁrst day, 12.3 h [SD, 6.7 h]) for a med-
ian duration of 5.0 days. In another study done by Carlucci
Aetal [24] the mean length of NIV according to the reason
for mechanical ventilation was 6.3 days (range: 1–29 days) in
hypoxemic ARF, 5.6 days (range: 1–24 days) in hypercapnic
ARF, and 2.4 days (range: 1–6 days) in pulmonary edema
(Tables 8 and 9).
The length of Intensive Care Unit (ICU) stay in group I was
signiﬁcantly shorter in group I compared to group II (p 0.001).
This is explained by the faster improvement in patients of
group I and less incidence of intubation and mechanical venti-
lation which deﬁnitely lead to the prolongation of ICU stay in
group II .Comparing the length of ICU stay in group II where
we apply NIPPV without FOB with another similar matching
group of NIPPV in Carlucci A et al. [24] study, a high degree
of similarity exists as the length of stay in the present study was
ranging from 4.0 to 35.0 days with a mean value of
8.68 ± 7.18 days while it was 8. 6 ± 6.3 days in the NIPPV
group in the other study.
Only one case (4%) in group I died versus 3 cases (12%) in
group II with no signiﬁcant statistical difference between both
groups (p= 0.609). Comparing the mortality in group I to the
mortality in Scala et al.’s [16] study, where 3 out of 15 patients
(20%) died, it was found that it is much less in our study. This
can be attributed to the etiology of decompensation in scala study
was community acquired pneumonia while in my study was dif-
ferent factors less in severity. However, the interpretation of data
in this limited number of patients is unreliable. The mortality in
group II (12%) came in agreement with most of the studies
applied on NIPPV for hypercapnic respiratory failure, as an
example the mortality in Carlucci A et al. [24] study was 10%
(5 out of 50 patients). Minor change in this percentage of mortal-
ity between different studies can be understood in the light of dif-
ferent levels of care and experience in different centers as well as
different baseline characteristics of the studied groups of patients.
Finally, it is obvious that the application of FOB was safe
and beneﬁcial for patients in the present study in terms of out-
come and also in reducing the economic burden of patient care
by reducing the number of patients who need invasive mechan-
ical ventilation as well as shorter stay in ICU. However, the
selection of patients -managed by NIPPV in whom application
of FBO will be beneﬁcial remains a clinical decision to be done
by the treating physician based on the overall clinical condition
of the patient and his initial response to treatment on NIPPV
and also the available resources and the skills of the physician
in the provision of FOB with minimal risk of complications.
With the application of more randomized clinical trials on the
role of bronchoscopy in the setting of AHRF, a clear consensus
and precise guidelines might develop in the future emphasizing
its application as a standard of care during NIPPV.
The limitations of the study are related mainly to the lim-
ited sample size of 50 patients (25 cases and 25 controls). How-
ever, this can be explained by the difﬁcult recruitment of
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study as the 50 patients were recruited over a period of
18 months, considering also the novelty of the research as it
was the ﬁrst time – to the best of our knowledge – to
investigate the role of FBO during NIPPV in AECOPD
patients as Scala et al.’s [16] study published in 2010 did not
compare between two groups of patients of NIPPV as we
did. The control group in Scala et al.’s [16] study was patients
on invasive ventilation. We totally agree that this study was
very important and a pioneer but we are claiming that our
study design and objectives are more reasonable and the
results we reached in our pilot study can be considered a pre-
liminary cornerstone and starting point for further investiga-
tions in the same topic through a multicenter study to
provide adequate sample size in a reasonable duration.
Another limitation is related to some technical difﬁculties in
the early provisionofFBOduring the course ofNIPPVaswewere
planning to do the procedure within the ﬁrst 6 h from the patient
admission. However, the unavailability of skilled personnel to do
the bronchoscopy in a safe way in many times delayed the proce-
dure to 2–6 h more than the initial plan, all patients who
underwent bronchoscopy later than 12 h from admission were
omitted from the study. In another study done by Hans Jo¨rg
et al. [22] on the role of the FOB in patients with acutehypoxemic
respiratory failure requiring NIPPV the median duration of con-
tinuous NIV prior to bronchoscopy was 10.5 h.
The last considered limitation in the present study is the
unavailability of the sedative drug dexmedetomidine (prece-
dex) in the Egyptian market which would be deﬁnitely a better
choice to provide adequate and safe sedation during FOB
without compromising the respiration or cardiovascular stabil-
ity of the patients. However, with the provision of titrated
sedation of midazolam under the supervision of highly experi-
enced intensivists, we were able to provide adequate sedation
during bronchoscopy with no serious complications [25,26].Conﬂict of interest
None.
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